SubsidieMeestersThe ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.
Projectdetails
Introduction
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases.
Need for New Targets
To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked.
PROSION's Solution
PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat diseases.
Applications of ProMs
ProMs can be combined into small molecule drugs to target proteins that play a key role in pathologies such as:
- Cancer
- Alzheimer’s
- Cardiovascular diseases
- Immune mediated disorders
Current Validation
The platform’s potential is currently being validated. In its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.461.375 |
| Totale projectbegroting | € 3.516.250 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- PROSION GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC STG | € 1.499.625 | 2022 | Details |
Protease Profiling and Triggered Drug Delivery for Personalized Cancer TherapyPROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery. | ERC COG | € 1.842.642 | 2022 | Details |
Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancerThe project aims to enhance understanding of proteasome activity in cancer through MAPP technology, exploring its role in tumor-immune interactions and potential for improving immunotherapy outcomes. | ERC COG | € 1.978.750 | 2022 | Details |
A general approach for the design of covalent protein proximity inducersThis project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications. | ERC COG | € 1.998.744 | 2024 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.
Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy
PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.
Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancer
The project aims to enhance understanding of proteasome activity in cancer through MAPP technology, exploring its role in tumor-immune interactions and potential for improving immunotherapy outcomes.
A general approach for the design of covalent protein proximity inducers
This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.